Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit

Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.

The annual World Bispecific Summit aiming to promote the development of bispecific antibody therapies will take place for the 12th time this year. It has become a prestigious platform in the industry for academic exchanges. The upcoming event will take place online from September 29 to October 1, 2021 Eastern Standard Time.

Details of the oral presentation by Boan Biotech are as follows:

Title: Optimization of CD3+ T-cell Engager to Improve Safety Profile
Session: T-cell Based Approaches for Oncology Therapeutics
Time: October 1, 2021


CD3+ T-cell engagers are a group of the most promising bispecific antibodies for the treatment of cancers. But they face major challenges including the dose-limiting, life threatening cytokine release syndrome (CRS) toxicity, suboptimal potency, and the on-target off-tumor toxicity. To overcome those challenges, Boan Biotech developed an optimized platform for CD3+ bispecific T-cell engagers with a unique combination of high potency, reduced cytokine release and tumor-targeting selectivity. 

The CEA/ CD3 bispecific antibody BA1202 is the first clinical candidate developed on the leading bispecific T-cell Engager platform. The pre-clinical research data of BA1202 showed a high potency in killing cancer cells, significantly reduced cytokine release, and superior efficacy.

In addition to BA1202, multiple bispecific antibody candidates with similar optimized format and the reduced CD3 affinity have been validated both in vitro and in vivo to have a similar advantage against different solid tumor targets. Boan Biotech plans to speed up the effort to take these bispecific T-cell engagers as investigational drugs to clinical trials, to address the huge unmet needs in treating patients with late-stage cancers.

About Boan Biotech

As a subsidiary of Luye Pharma Group, Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on oncology, immunology, pain, and endocrine diseases. Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform. The company has developed more than 10 innovative antibody product candidates with international intellectual property protection, and 8 biosimilar product candidates, one of which ? Boyounuo (Bevacizumab Injection) ? has been launched in China.

Boan Biotech has expertise in the full industry chain: antibody generation, lead optimization, cell line development, process development, technology transfer, pilot and commercial scale production. The company is also actively exploring other cutting-edge technologies. Its cell therapy products use non-viral vectors for CAR-T for late stage solid tumors. In addition, Boan Biotech is exploring novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients. Outside of China, Boan Biotech also pursues biopharmaceutical products development in the US and EU markets.

SOURCE Luye Pharma Group

These press releases may also interest you

at 22:55
The Pharmaceutical Formulation market is growing at a CAGR of 6.23% during the five-year forecast period. A targeted strategic approach to Pharmaceutical Formulation sourcing can unlock several opportunities for buyers. This report also offers market...

at 20:57
The Salt River Pima-Maricopa Indian Community ("SRPMIC") has awarded a grant of $50,000 to the Veterans Medical Leadership Council (VMLC), through their 12% Gaming Grant Program. The VMLC supports Veterans of any era who have a verified and bonified...

at 20:36
Thermo Fisher Scientific Inc. ("Thermo Fisher") announced today that it has priced an offering of $5.85 billion aggregate principal amount (the "Offering") of the following notes, each issued at par: $1,000,000,000 aggregate principal amount of its...

at 20:26
Molecular Lab Partners LLC, a national provider of turn-key Physician Office Laboratory (POL) Solutions, announced strong growth during the third quarter of 2021. The company achieved 86% revenue growth during the quarter.  The growth is reflective...

at 20:00
The sexual wellness market is expected to grow by USD 32.02 billion from 2021-2025, progressing at a CAGR of 10.86% according to the latest market report by Technavio....

at 19:45
Heart to Heart Hospice, a leader in hospice services since 2003, will soon be opening a new Hospice Inpatient Center in Houston. The facility is located inside Proveer at Northgate (formerly Pathways Memory Care) at 2930 Cypress Grove Meadows Drive....

News published on 25 september 2021 at 22:12 and distributed by: